Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome

Clin Exp Pharmacol Physiol. 2023 Nov;50(11):835-843. doi: 10.1111/1440-1681.13814. Epub 2023 Aug 21.

Abstract

Berberine (BBR) is an isoquinoline alkaloid extracted from Chinese medicinal plants showing a tight correlation with gut microbiota. Polycystic ovary syndrome (PCOS) is a prevalent reproductive and endocrine disorder syndrome among women of childbearing age. Dysbiosis, the imbalance of intestinal microorganisms, is a potential factor that takes part in the pathogenesis of PCOS. Recent evidence indicates that berberine offers promise for treating PCOS. Here, we review the recent research on the interaction between berberine and intestinal microorganisms, including the changes in the structure of gut bacteria, the intestinal metabolites after BBR treatment, and the effect of gut microbiota on the bioavailability of BBR. We also discuss the therapeutic effect of BBR on PCOS in terms of gut microbiota and its potential mechanisms.

Keywords: berberine; gut microbiota; insulin resistance; polycystic ovary syndrome.

Publication types

  • Review